JP6531100B2 - キナーゼ阻害剤としての置換ニコチンアミド誘導体 - Google Patents
キナーゼ阻害剤としての置換ニコチンアミド誘導体 Download PDFInfo
- Publication number
- JP6531100B2 JP6531100B2 JP2016538520A JP2016538520A JP6531100B2 JP 6531100 B2 JP6531100 B2 JP 6531100B2 JP 2016538520 A JP2016538520 A JP 2016538520A JP 2016538520 A JP2016538520 A JP 2016538520A JP 6531100 B2 JP6531100 B2 JP 6531100B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- phenyl
- ethynyl
- oxide
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- GERGEMKRCKGUFR-UHFFFAOYSA-N CCOC(CNC(N(CC1)CCS1(=NC(c1cncc(C#Cc2cccc(NC(c3c(C)cc[o]3)=O)c2)c1)=O)=O)=O)=O Chemical compound CCOC(CNC(N(CC1)CCS1(=NC(c1cncc(C#Cc2cccc(NC(c3c(C)cc[o]3)=O)c2)c1)=O)=O)=O)=O GERGEMKRCKGUFR-UHFFFAOYSA-N 0.000 description 1
- FLVFPAIGVBQGET-UHFFFAOYSA-N CN(CC1)CC1O Chemical compound CN(CC1)CC1O FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 description 1
- WOMTYMDHLQTCHY-UHFFFAOYSA-N CNCC(CO)O Chemical compound CNCC(CO)O WOMTYMDHLQTCHY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915186P | 2013-12-12 | 2013-12-12 | |
| US201361915209P | 2013-12-12 | 2013-12-12 | |
| US61/915,209 | 2013-12-12 | ||
| US61/915,186 | 2013-12-12 | ||
| PCT/US2014/069601 WO2015089220A1 (en) | 2013-12-12 | 2014-12-10 | Substituted nicotinamide derivatives as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539995A JP2016539995A (ja) | 2016-12-22 |
| JP2016539995A5 JP2016539995A5 (https=) | 2019-04-11 |
| JP6531100B2 true JP6531100B2 (ja) | 2019-06-12 |
Family
ID=52118045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538520A Expired - Fee Related JP6531100B2 (ja) | 2013-12-12 | 2014-12-10 | キナーゼ阻害剤としての置換ニコチンアミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150166518A1 (https=) |
| EP (1) | EP3080084B1 (https=) |
| JP (1) | JP6531100B2 (https=) |
| CN (1) | CN105814021B (https=) |
| AU (1) | AU2014362391B2 (https=) |
| BR (1) | BR112016013539A2 (https=) |
| CA (1) | CA2932831A1 (https=) |
| WO (1) | WO2015089220A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011153419A2 (en) | 2010-06-03 | 2011-12-08 | Midtronics, Inc. | Battery pack maintenance for electric vehicle |
| US11740294B2 (en) | 2010-06-03 | 2023-08-29 | Midtronics, Inc. | High use battery pack maintenance |
| US10046649B2 (en) | 2012-06-28 | 2018-08-14 | Midtronics, Inc. | Hybrid and electric vehicle battery pack maintenance device |
| DE112012004706T5 (de) | 2011-11-10 | 2014-08-21 | Midtronics, Inc. | Batteriepack-Testvorrichtung |
| US11325479B2 (en) | 2012-06-28 | 2022-05-10 | Midtronics, Inc. | Hybrid and electric vehicle battery maintenance device |
| US10843574B2 (en) | 2013-12-12 | 2020-11-24 | Midtronics, Inc. | Calibration and programming of in-vehicle battery sensors |
| US10473555B2 (en) | 2014-07-14 | 2019-11-12 | Midtronics, Inc. | Automotive maintenance system |
| WO2016123075A1 (en) | 2015-01-26 | 2016-08-04 | Midtronics, Inc. | Alternator tester |
| US10608353B2 (en) | 2016-06-28 | 2020-03-31 | Midtronics, Inc. | Battery clamp |
| US12320857B2 (en) | 2016-10-25 | 2025-06-03 | Midtronics, Inc. | Electrical load for electronic battery tester and electronic battery tester including such electrical load |
| US11054480B2 (en) | 2016-10-25 | 2021-07-06 | Midtronics, Inc. | Electrical load for electronic battery tester and electronic battery tester including such electrical load |
| CN108456163A (zh) | 2017-02-20 | 2018-08-28 | 中国科学院上海药物研究所 | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 |
| US11513160B2 (en) | 2018-11-29 | 2022-11-29 | Midtronics, Inc. | Vehicle battery maintenance device |
| CN111662227B (zh) * | 2019-03-06 | 2022-07-05 | 中国科学院上海药物研究所 | 邻氨基吡啶炔类化合物及其制备方法和用途 |
| US11566972B2 (en) | 2019-07-31 | 2023-01-31 | Midtronics, Inc. | Tire tread gauge using visual indicator |
| US11545839B2 (en) | 2019-11-05 | 2023-01-03 | Midtronics, Inc. | System for charging a series of connected batteries |
| US11668779B2 (en) | 2019-11-11 | 2023-06-06 | Midtronics, Inc. | Hybrid and electric vehicle battery pack maintenance device |
| US11474153B2 (en) | 2019-11-12 | 2022-10-18 | Midtronics, Inc. | Battery pack maintenance system |
| DE102020216599A1 (de) | 2019-12-31 | 2021-07-01 | Midtronics, Inc. | Intelligente Modulschnittstelle für eine Batteriewartungsvorrichtung |
| US11973202B2 (en) | 2019-12-31 | 2024-04-30 | Midtronics, Inc. | Intelligent module interface for battery maintenance device |
| US11486930B2 (en) | 2020-01-23 | 2022-11-01 | Midtronics, Inc. | Electronic battery tester with battery clamp storage holsters |
| US12517178B2 (en) | 2021-05-27 | 2026-01-06 | Midtronics, Inc. | Battery monitoring system |
| US12555965B2 (en) | 2021-08-24 | 2026-02-17 | Midtronics, Inc. | Power adapter for automotive vehicle maintenance device |
| US12330513B2 (en) | 2022-02-14 | 2025-06-17 | Midtronics, Inc. | Battery maintenance device with high voltage connector |
| US12392833B2 (en) | 2022-05-09 | 2025-08-19 | Midtronics, Inc. | Electronic battery tester |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2669704A1 (en) * | 2006-11-16 | 2008-05-22 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| US8558002B2 (en) * | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
-
2014
- 2014-12-10 US US14/565,689 patent/US20150166518A1/en not_active Abandoned
- 2014-12-10 WO PCT/US2014/069601 patent/WO2015089220A1/en not_active Ceased
- 2014-12-10 AU AU2014362391A patent/AU2014362391B2/en not_active Ceased
- 2014-12-10 JP JP2016538520A patent/JP6531100B2/ja not_active Expired - Fee Related
- 2014-12-10 CN CN201480066924.XA patent/CN105814021B/zh not_active Expired - Fee Related
- 2014-12-10 EP EP14815201.0A patent/EP3080084B1/en not_active Not-in-force
- 2014-12-10 CA CA2932831A patent/CA2932831A1/en not_active Abandoned
- 2014-12-10 BR BR112016013539-3A patent/BR112016013539A2/pt not_active Application Discontinuation
-
2016
- 2016-03-14 US US15/069,344 patent/US9567324B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160194311A1 (en) | 2016-07-07 |
| CA2932831A1 (en) | 2015-06-18 |
| US20150166518A1 (en) | 2015-06-18 |
| AU2014362391A1 (en) | 2016-06-16 |
| AU2014362391B2 (en) | 2019-04-04 |
| EP3080084A1 (en) | 2016-10-19 |
| EP3080084B1 (en) | 2018-06-13 |
| CN105814021A (zh) | 2016-07-27 |
| BR112016013539A2 (pt) | 2020-10-27 |
| WO2015089220A1 (en) | 2015-06-18 |
| JP2016539995A (ja) | 2016-12-22 |
| CN105814021B (zh) | 2020-03-13 |
| US9567324B2 (en) | 2017-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6531100B2 (ja) | キナーゼ阻害剤としての置換ニコチンアミド誘導体 | |
| CN106536508B (zh) | 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的化合物 | |
| AU2007319151B2 (en) | Sulfoximines as kinase inhibitors | |
| JP5412430B2 (ja) | mGlu5拮抗薬としての新規複素環系化合物 | |
| JP6531101B2 (ja) | キナーゼ阻害剤としての置換ジアルキル(オキシド)−∧4−スルファニリデンニコチンアミド誘導体 | |
| CA2853062A1 (en) | Pyridine- sulfoximines as tyrosine kinase inhibitors | |
| Intagliata et al. | Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT7R selective ligands over 5-HT1AR | |
| ES2623652T3 (es) | Derivados de 3-fenil-5-ureidoisotiazol-4-carboximida y 3-amino-5-fenilisotiazol como inhibidores de cinasa | |
| US20180111921A1 (en) | Pyridyl benzothiophenes as kinase inhibitors | |
| HK1227390A1 (en) | Substituted nicotinamide derivatives as kinase inhibitors | |
| HK40043779A (en) | Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors | |
| HK1227390B (zh) | 作为激酶抑制剂的取代的烟酰胺衍生物 | |
| HK1228396A1 (en) | Substituted dialkyl(oxido)-λ4-sulfanylidene nicotinamide derivatives as kinase inhibitors | |
| JP2005538996A (ja) | 化合物 | |
| HK1228396B (zh) | 作为激酶抑制剂的取代的二烷基(氧撑)-λ4-硫烷亚基烟酰胺衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171211 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180820 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180823 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190220 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20190220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190418 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190520 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6531100 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |